Liver metastases in colorectal cancer. Reply to figueras et al

Maurel J, Reguart N. Optimal treatment for poor prognosis isolated colorectal liver metastases. Rationality for prospective neoadjuvant clinical trials. Rev Oncologia 2001; 3: 72–78.

Figueras J, Torras J, Valls C, et al. Factores pronósticos e indicaciones quirúrgicas en las metástasis hepáticas de carcinoma colorrectal. Rev Oncologia 2001; 2: 309–315.

Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 214: 509–522.

Balalakos EA, Kim JA, Young DC, et al. Determinants of survival following hepatic resectin for metastatic colorectal cancer. World J Surg 1998; 22: 399–404.

Minagawa M, Makuuchi M, Tozilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Am Surg 2000; 231: 487–499.

Scheele J, Stang R, Alteendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. Word J Surg 1995; 19: 59–71.

Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic mestastases from colorectal cancer. N Engl J Med 1999; 341: 2.039–2.048.

Kemeny MM, Adak S, Lipsitz S, et al. Results of the intergroup (ECOG and SWOG) prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continucus hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases. Proc Am Soc Clin Oncol 1999; 18: 1012 (abstract).

Lorenz M, Miller HH, Schramm H, et al. Randomized trial of surgery versus surgery followe by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperation on Liver metastases. Ann Surg 1998; 228: 756–62.